EvoLiver™ is the flagship blood test in our oncology and cardiometabolic product portfolio, built on Mursla Bio's proprietary AI Precision Medicine Platform.
EvoLiver™ is designed to detect liver cancer early in high risk populations, when clinical action can make the greatest difference.
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first in five years for any test in the liver cancer surveillance space.
EvoLiver™ is
EvoLiver™ is designed to detect liver cancer early in high risk populations, when clinical action can make the greatest difference.
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first in five years for any test in the liver cancer surveillance space.
Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.
For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer.
However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound.
As part of normal biology, cells release extracellular vesicles (EVs), tiny membrane-bound particles that carry intact proteins, RNAs, lipids, and metabolites reflecting active cellular processes. Every organ sheds its own population of EVs into the bloodstream, creating a molecular footprint of tissue-specific activity accessible through a simple blood draw.
These organ-derived EVs provide a non-invasive window into the molecular state of internal organs, offering new opportunities to track disease biology, detect early pathological changes, and monitor therapeutic response directly from blood without requiring tissue biopsy.
For more visual explanations, please watch our 3D video.
Mursla Bio’s AI Precision Medicine Platform relies on first-in-class isolation of organ-specific EVs directly from blood, creating biologically labeled, tissue- specific molecular datasets.
Machine learning enhances multiomic profiling across proteomics and small RNA sequencing, enabling robust biomarker discovery from minimal plasma volumes and smaller patient cohorts.
Validated signatures are translated into scalable, cost-efficient in vitro diagnostic (IVD) assays ready for clinical deployment. The platform supports longitudinal disease tracking and AI-powered patient stratification across multiple organ systems.
It has already enabled the development of EvoLiver™, a blood-based test for early liver cancer detection recently granted FDA Breakthrough Device Designation.
EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …